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Introduction: Lung cancer with breast metastasis is rare. However, 
differentiating between primary breast cancer and metastatic lung 
adenocarcinoma is of clinical importance. The metastasis cascade of 
how cancer cells migrate from the primary lung tumor to the breast 
is not clear yet.
Methods: Pathology and cytology databases were searched for 
patients diagnosed to have lung adenocarcinoma with breast metasta-
sis. Their medical records, chest computed tomography images, and 
pathology slides were reviewed independently.
Results: We identified six lung adenocarcinoma patients with 
breast metastases in a 10-year period from a tertiary medical cen-
ter. Interestingly, all breast metastases affected the same side as the 
primary lung cancers. In addition, all our cases shared other clini-
cal manifestations, namely, ipsilateral pleural effusion/thickness and 
axillary lymph node enlargement.
Conclusion: Because this distinctive feature could not be explained 
by simple coincidence, we consider that lung adenocarcinoma may 
preferentially metastasize to the ipsilateral breast through a stepwise 
mechanism, involving pleural seeding, axillary lymph node metasta-
sis, and retrograde lymphatic spreading into the breast.
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Lung cancer is a highly malignant disease and usually, has widespread metastasis at initial presentation or during treat-
ment course. The most commonly affected metastatic organs 
include lymph node, bone, lung, brain, liver, and adrenal 
gland. In fact, almost every organ could have been metasta-
sized at late-stage disease. Although lung adenocarcinoma 
rarely metastasizes to the breast, it is of great clinical signifi-
cance to differentiate primary from metastatic lesions because 
primary breast adenocarcinoma is a common malignancy with 
very different management and outcome. Traditionally, an 
ancillary panel of immunohistochemical staining can provide 
enough information for the differential diagnosis. Nowadays, 
because of advances in molecular pathology, specific genetic 
alterations, such as activating epidermal growth factor receptor 
(EGFR) mutations, may give an additional diagnostic clue to 
elucidate the origin of the cancer cells.
It is believed that cancer cells metastasize to regional 
lymph nodes through lymphatic channels, and metastasize to 
distant organs through hematogenous spreading. Although 
cancer cells continuously shed from the primary tumor and 
circulate around the body, only infrequently would they 
adhere to vessel wall, undergo extravasation, and develop 
overt metastasis.1 This tightly regulated interaction between 
cancer cells and microenvironment, the so-called seed and 
soil hypothesis, shows why cancer cells preferentially metas-
tasize to some organs but not the others.
For symmetrically paired organs with similar volumes, 
such as breasts, it is expected that metastases for any given 
malignancy through hematogenous spread would affect either 
breast equally. On the contrary, if the metastasis occurs pre-
dominantly in one of the paired organs, it may imply that 
hematogenous spread is not the predominant route for metas-
tasis. Recently, we observed a case of primary lung adeno-
carcinoma with metastasis at the ipsilateral breast. Because 
a previous study had shown that breast cancer predominantly 
affected the ipsilateral pleural cavity,18 we then initiated a 
study to investigate the laterality of primary lung adenocarci-
noma and its breast metastasis in our patients.
PATIENTS AND METHODS
To identify lung adenocarcinoma patients with breast 
metastasis, we used the pathology database at the Department 
of Pathology and Laboratory Medicine of the Taipei Veterans 
General Hospital. The case-finding algorithm were: 1) using 
“breast” as the key word for “type of specimen” and 2) using 
“metastatic carcinoma” as the key words for “diagnosis.” 
We also used the cytology database at the Department of 
Chest Medicine. Because most patients in this database were 
diagnosed with primary lung cancer, we retrieved data of all 
cases whose specimen type was breast and the diagnosis was 
carcinoma. We then reviewed the medical records of these 
patients to determine the origin of the breast carcinomas. 
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Only patients diagnosed with primary lung adenocarcinoma 
were included for further analysis. Serial chest computed 
tomography (CT) images of each case, at initial diagnosis and 
during treatment, were reviewed independently by two authors 
(CHC and WMH). This study was approved by the Institutional 
Review Board of Taipei Veterans General Hospital (approval 
number, 2012-04-027BC).
RESULTS
The index case was a 70-year-old woman, who pre-
sented with a centrally located lung adenocarcinoma at left 
upper lobe accompanied by ipsilateral malignant pleural 
effusion. After four cycles of chemotherapy with cisplatin 
and vinorelbine, she noted a painless lump in her left breast. 
Physical examination revealed a fixed hard mass at the upper 
outer quadrant of her left breast and a palpable lymph node 
in the left axilla. Because of her history of lung cancer, core-
needle biopsy was performed before the planned surgical 
resection. Pathology disclosed atypical glands in the breast 
parenchyma (Fig. 1A). These atypical cells were immuno-
reactive for TTF-1 (Fig. 1B) and negative for ER, PR, and 
GCDFP-15 (Fig. 1C). Further, EGFR gene sequencing showed 
missense point mutation L858R at exon 21, the same muta-
tion as the original lung tumor. The final diagnosis of the left 
breast mass was metastatic adenocarcinoma originating from 
lung. Because of disease progression, the patient’s treatment 
was shifted to erlotinib. After a 3-month course of treatment, 
follow-up chest CT scan showed significant reduction of the 
primary lung tumor, the metastatic breast lesion, and axillary 
lymph node (Fig. 2).
During 2001–2011, five additional lung adenocarci-
noma patients with breast metastasis were identified from the 
cytology and pathology database. The clinical characteris-
tics are summarized in Table 1. All patients were women and 
shared some clinical similarities: 1) breast metastasis was at 
the same side as the primary lung carcinoma, 2) presence of 
enlarged ipsilateral axillary lymph nodes, and 3) presence of 
ipsilateral pleural effusion and/or thickening (Fig. 3).
DISCUSSION
Breast metastasis from extramammary malignancy 
is rare.2 Although it represents only approximately1% of all 
breast malignancies, differentiating primary from metastatic 
FIGURE 1. A, Photomicrograph of a representative case shows atypical glands (right upper quadrant) in the breast paren-
chyma (hematoxylin and eosin stain, 100×). B, These cancer cells are highlighted by nuclear staining with TTF-1. C, The atypical 
glands are not immunoreactive to GCDFP-15 staining; on the contrary, the normal mammary gland is (left lower quadrant). D, 
Tumor emboli is observed in a lymphatic vessel, which is demonstrated by D2-40 immunostaining. HE, hematoxylin and eosin; 
TTF-1, ;GCDFP-15, .
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mammary carcinoma is of great clinical significance because 
of the differing management options. Morphologically, elas-
tosis and carcinoma in situ, which are common in primary 
mammary carcinoma, are extremely rare in breast metastasis.3 
The result of an immunohistochemical panel is a useful supple-
ment in differential diagnosis. Primary mammary carcinoma 
FIGURE 2. A, Pretreatment chest CT scan. B, Posttreatment chest CT scan shows tumor reduction of the primary lung cancer 
(arrow head), the breast metastasis (thick arrow), and the axillary lymph node (thin arrow). CT, computed tomography.
TABLE 1.  Clinical Characteristics of Patients with Lung Adenocarcinoma and Breast Metastasis in Previous Reports  
and Current Study
Sex Age (yr)
Laterality
Axillary LN
Pleural  
Effusion/Thickness
Lung  
Cancer
Breast  
Metastasis
Verger et al.5 M 63 Right Left ? ?
Ramar et al.6 M 56 Right Right ? ?
Gómez-Caro et al.7 M 65 Left Left — ?
Rimner et al.8 F 81 Left Left +, Left +, Left
Ucar et al.9 M 63 Left Left ? +, Left
Ho et al.10 M 71 Right Left +, Side? +, Right
Yoon et al.11 F 42 Left Left ? ?
Maounis et al.12 F 73 Left Left +, Left +, Left
Li et al.13 F 53 Left Left +, Left +, Left
Fukumoto et al.16 F 65 Left Left ? ?
Hsu et al.17 F 80 Left Left ? +, lLft
F 83 Right Right ? +, Right
F 43 Right Left ? ?
This study F 70 Left Left +, Left +, Left
F 48 Right Right +, Right +, Right
F 43 Right Right +, Right +, Right
F 54 Left Left +, Left +, Left
F 52 Left Left +, Left +, Left
F 43 Left Left +, Left +, Left
?, unknown; F, female; LN, lymph node; M, male.
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is frequently immunoreactive for ER, PR, and GCDFP-15. 
However, S100, WT-1, PSA, and TTF-1 are the representative 
markers for melanoma, ovarian serous papillary carcinoma, 
prostate carcinoma, and lung adenocarcinoma, respectively. In 
some patients, such as our index case, specific gene mutation 
could provide additional evidence for the origin of the can-
cer cells. Classic activating EGFR mutations at the tyrosine 
kinase domain occur almost exclusively in lung adenocarci-
nomas, as in our index patient, and are not seen in primary 
mammary carcinomas.4
We searched our pathology and cytology database to 
determine the crude incidence of breast metastasis in lung 
adenocarcinoma patients in the past 10 years in our institute. 
From approximately 6000 cases, we identified a total of six 
cases; to our surprise, they shared some clinical similarities. 
First, breast metastases were all at the same side as their pri-
mary lung cancers. In addition, they all had ipsilateral axil-
lary lymphadenopathy, and interestingly, ipsilateral pleural 
effusion and/or pleural thickening. We reviewed the literature 
for similar case reports, which gave detailed clinical data 
regarding the laterality of the primary lung cancer and breast 
metastasis. As of January 2013, 13 cases were identified and 
remarkably, 10 of them also showed ipsilateral breast metasta-
ses as ours (Table 1).5–13,16,17
The most common modes of lung cancer metastasis are 
direct invasion, pleural seeding, hematogenous dissemination, 
and lymphatic spreading. If lung adenocarcinoma metasta-
sizes to the breast predominantly through hematogenous dis-
semination, the chance of either breast being affected should 
be equal. Under this premise, the probability of six lung 
adenocarcinoma patients to have ipsilateral breast metastases 
would be 1.6% (0.56 = 0.016). Direct tumor invasion is proba-
bly the simplest explanation for ipsilateral breast involvement; 
however, chest CT of our cases indicated this to be unlikely 
because the fat planes between the chest wall and breast tis-
sue were all intact (Figs. 2 and 3). Hence, lymphatic spread-
ing might be the most plausible route. Indeed, intralymphatic 
tumor emboli could be easily demonstrated by D2-40 immu-
nostaining, a marker for lymphatic endothelium, in our cases 
(Fig. 1D). Similar findings have also been reported by Ho et 
al.10 In fact, using 99mTc-antimony colloid SPECT/CT scan, 
Barber et al.14 demonstrated a communication of breast lym-
phatic drainage with the intrapulmonary lymphatic system in 
a breast cancer patient. They considered this communication a 
potential mechanism for the presence of metastatic mediasti-
nal lymphadenopathy in breast cancer patients. Therefore, it is 
possible that lung cancer may metastasize retrogradely to the 
ipsilateral breast through the same lymphatic channel.
However, we consider the mechanism being more com-
plicated because all our cases had simultaneous ipsilateral 
pleural and axillary lymph node metastases (Table 1). It is 
plausible that established breast metastases may further drain 
to axillary lymph nodes just as primary mammary carcinomas 
do. Nevertheless, if this is true, it would be more common to 
see breast than axillary lymph node metastases, which is not 
consistent with our clinical experience. In addition, in some 
of our cases, serial chest CT scans showed that axillary lymph 
node enlargement appeared before the occurrence of breast 
FIGURE 3.  The other five cases share with the index case the same clinical manifestations, including ipsilateral pleural effusion/
thickening, enlarged axillary lymph node (middle panel), and breast metastasis (lower panel).
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nodules. Therefore, we hypothesize that lung cancer cells may 
predominantly metastasize to ipsilateral axillary lymph nodes 
first, then spread retrogradely to the intramammary lymphatic 
system, and finally establish breast metastasis. In fact, this ret-
rograde lymphatic spreading has also been observed in other 
types of cancer.19,20
Previous studies have suggested a lymphatic drainage 
from mediastinal lymph nodes, through intercostal and/or 
supraclavicular lymphatic vessels, to ipsilateral axillary lymph 
nodes (Fig. 4A).15 Alternatively, we propose that lung cancer 
cells might first result in malignant pleural effusion, seed on 
the parietal pleura, invade the lymphatic vessels in chest wall, 
and then drain off to ipsilateral axillary lymph nodes (Fig. 4B). 
The latter pathway may explain the unique presentation of the 
clinical trio of ipsilateral pleural effusion/thickness, axillary 
lymph node enlargement, and breast metastasis, in all our 
cases.
Although the mechanism is still hypothetical, our clini-
cal observations strongly suggest that one should carefully 
examine the ipsilateral axillary lymph node and breast when 
treating a lung adenocarcinoma patient with pleural metasta-
sis and/or chest wall invasion. However, there are limitations 
in this study. Above all, the case numbers are very small, and 
therefore, the statistical errors could be high. In addition, there 
is no any objective molecular evidence supporting our pre-
sumptive metastatic cascade. Recently, it has been shown that 
new genomic strategies could help to elucidate the clonal evo-
lution of cancer,21,22 which may aid to determine the metastatic 
cascade in the future studies.
In conclusion, although breast metastasis from lung 
cancer is rare, an accurate diagnosis is of great clinical impor-
tance. In addition to the morphological and immunohisto-
chemical characteristics, EGFR gene sequencing may provide 
another clue to the diagnosis. Cancer cells can metastasize 
to either breast through the hematogenous route; however, in 
lung adenocarcinoma, cells seem to preferentially spread to 
the ipsilateral breast, probably through a retrograde axillary 
lymphatic drainage.
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